Dosing commences in Bio-Thera’s Phase I solid tumour study of BAT8013
The Phase I trial aims to determine maximum tolerated dose, evaluate pharmacokinetics, and gather preliminary efficacy data.
Analysis
View MoreAPIs to the rescue?
Oral bioavailability remains one of the biggest challenges in drug development, particularly for small-molecule APIs with poor solubility or permeability. Liam Critchley explores how pharmaceutical companies are using integrated formulation...
AI now: What QbD and PAT missed
Cool heads, smart chains
Sustainability vs suitability
Integrating sustainability compliance